Human immunoglobulin versus plasmapheresis in guillain-barre syndrome and myasthenia gravis: A meta-analysis

Journal of Clinical Neuromuscular Disease

Volumn 18, Issue 1, 2016, Pages 1-11

  Ortiz Salas, Paola ^a   Velez Van Meerbeke, Alberto ^a   Galvis Gomez, Camilo Alberto ^a   Rodriguez, Jesús H ^a  

^a UNIVERSIDAD DEL ROSARIO   (Colombia)

Author keywords

Adverse effects; Autoimmune neurologic diseases; Efficacy; Immunoglobulin; Plasma exchange

Indexed keywords

ALBUMIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN;

ACUTE KIDNEY FAILURE; ALLERGIC REACTION; ANEMIA; ARTICLE; ARTIFICIAL VENTILATION; BODY WEIGHT; CHILL; DIARRHEA; DISABILITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FAINTNESS; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HEART ARRHYTHMIA; HEMATOMA; HEMATURIA; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOTENSION; LENGTH OF STAY; MENINGISM; META ANALYSIS; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NAUSEA AND VOMITING; PHLEBITIS; PLASMAPHERESIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SENSITIVITY ANALYSIS; SEPSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASOSPASM; VEIN THROMBOSIS; VERTIGO; COMPARATIVE STUDY; GUILLAIN-BARRE SYNDROME; PROCEDURES;

GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYASTHENIA GRAVIS; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84983766452     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0000000000000119     Document Type: Article

References (41)

1. Anaya J. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev. 2012;11:781-784.
2. Lehmann HC, Hartung HP. Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies. J Neuroimmunol. 2011;231:61-69.
3. Cortese I, Chaudhry V, So Y, et al. Evidence-based guideline update: plasmapheresis in neurologic disorders. Neurology. 2011;76:294-300.
4. Raphaël J, Chevret S, Hughes R, et al. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012:CD001798.
5. Stangel M, Baumann U, Borte M, et al. Treatment of neurological autoimmune diseases with immunoglo-bulins: first insights from the prospective SIGNS registry. J Clin Immunol. 2013;33(suppl 1):S67-S71.
6. Hughes R, Dalakas M, Cornblath D, et al. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol. 2009;158(suppl 1):34-42.
7. Hughes R, Swan A, Van Doorn P. Intravenous immu-noglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2012:CD002063.
8. Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017-2023.
9. Bril V, Ilse WK, Pearce R, et al. Pilot trial of immu-noglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology. 1996; 46:100-103.
10. Diener H, Haupt W, Kloss T, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome. Eur Neurol. 2001;46:107-109.
11. El-Bayoumi M, El-Refaey AM, Abdelkader AM, et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care. 2011;15:R164.
12. Gajdos P, Chevret S, Clair B, et al. Clinical Trial of Plasma Exchange and high dose intravenous in myas-tenia gravis. Ann Neurol. 1997;41:789-796.
13. Hosokawa T, Hamaguchi K, Tomioka R, et al. Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report. Ther Apher. 1998;2:288-291.
14. Liu J, Wang W, Xue J, et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, Immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial. 2010;14:153-160.
15. Netto A, Kulkarni GB, Taly AB, et al. A comparison of immunomodulation therapies in mechanically ventilated patients with Guillain Barré syndrome. J Clin Neurosci. 2012 19:1664-1667.
16. Nomura K, Hamaguchi K, Hattori T, et al. A randomized controlled trial comparing intravenous immunoglobulin. Neurol Ther. 2001 1:69-81.
17. Ravasio A, Pasquinelli M, Currò Dossi B, et al. High dose intravenous immune globulins and plasma exchange in Guillain-Barré Syndrome. Ital J Neurol Sci. 1995 16:487-492.
18. Van der Meché F, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992;326: 1123-1129.
19. Alshekhlee A, Hussain Z, Sultan B, et al. Immunotherapy for Guillain-Barré syndrome in the US hospitals. J Clin Neuromusc Dis. 2008;10:4-10.
20. Hughes RAC, Swan AV; Group for Plasma Exchange/Sandoglobulin Guillain-Barre'Syndrome Trial. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre'syndrome. Lancet. 1997;25:225-230.
21. Mandawat A, Kaminski H, Cutter G, et al. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68:797-805.
22. Martínez Yélamos A, Huerta Villanueva M, Olivé Plana M, et al. Treatment of Guillain-Barré syndrome: immunoglobulins or plasmapheresis? Neurologia. 1998;13:166-169.
23. Murthy J, Meena A, Chowdary G, et al. Myasthenic crisis: clinical features, complications and mortality. Neurol India. 2005;53:37-40.
24. Oczko-Walker M, Manousakis G, Wang S, et al. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis. 2010;12:55-61.
25. Pérez Nellar J, Domínguez A, Llorens-Figueroa J, et al. A comparative study of intravenous immunoglobulin and plasmapheresis preoperatively in myasthenia. Rev Neurol. 2001;33:413-416.
26. Qureshi A Choudhry M, Akbar M, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology. 1999;52:629-632.
27. Rønager J, Ravnborg M, Hermansen I, et al. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001;25:967-973.
28. Tsai C, Wang K, Liu C, et al. Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin. J Clin Neurosci. 2007 14:625-629.
29. Vajsar J, Sloane A, Wood E, et al. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain-Barré síndrome. Arch Pediatr Adolesc Med. 1994;148:1210-1212.
30. Jensen P, Bril V. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J Clin Neuromuscul Dis. 2008;9:352-355.
31. Pittayanon R, Treeprasertsuk S, Phanthumchinda K. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn memorial hospital. J Med Assoc Thai. 2009;92:478-482.
32. Garvey M, Snider L, Leitman S, et al. Treatment of Sydenham's Chorea with intravenous immunoglobu-lin, plasma exchange, or prednisone. J Child Neurol. 2005;20:424-429.
33. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999;354:1153-1158.
34. Dyck P, Litchy W, Kratz K, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneurop-athy. Ann Neurol. 1994;36:838-845.
35. Gajdos P, Chevret S, Toyka K. Plasma exchange for generalised myasthenia gravis. Cochrane Database Syst Rev. 2002:CD002275.
36. Gajdos P, Chevret S, Toyka K. Intravenous immuno-globulin for myasthenia gravis. Cochrane Database Syst Rev. 2008:CD002277.
37. Cortese I, Cornblath D. Therapeutic plasma exchange in neurology: 2012. J Clin Apher. 2013; 28:16-19.
38. Patwa H, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2012;78:1009-1015.
39. Kaya E, Keklik M, Sencan M, et al. Therapeutic plasma exchange inpatients with neurological diseases: multicenter retrospective analysis. Transfuse Apher Sci. 2013;48:349-352.
40. Nagpal S, Benstead T, Shumak K, et al. Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis. J Clin Apher. 1999;14:107-113.
41. Heatwole C, Johnson N, Holloway R, et al. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. J Clin Neuromuscul Dis. 2011;13: 85-94.